Botanical Drugs Market
完整報告名稱與涵蓋範圍
Botanical Drugs Market Size, Share & Trends Analysis Report, By Source & Formulation (Single-Herb Extract Drugs, Multi-Herb Formulation Drugs, Cannabis-Derived Prescription Drugs, Topical Botanical Preparations, Oral Botanical Preparations), By Therapeutic Area (Dermatology & Wound Care, Gastroenterology, Neurology, Respiratory Disorders, Cardiovascular Support), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
Botanical drugs are plant-derived medicines approved through formal pharmaceutical pathways, such as the US FDA botanical drug guidance, Japan's prescription Kampo system, China's registered traditional medicine categories and Europe's well-established-use phytomedicine registrations. Unlike loosely regulated supplements, these are prescription and pharmacy-grade products with defined clinical evidence, standardised multi-constituent compositions and pharmaceutical-quality manufacturing controls, spanning topical dermatology and wound care agents, antidiarrhoeal and gastrointestinal therapies, cannabis-derived neurology treatments and multi-herb cardiovascular and respiratory formulations.
Growth rests on regulatory precedent: each approval, from green tea catechin ointments and crofelemer to purified cannabidiol and birch bark triterpene wound gels, demonstrates that heterogeneous plant compositions can satisfy modern efficacy and chemistry-manufacturing-controls standards, encouraging new botanical INDs. Demand-side mechanisms include physician and patient interest in plant-derived options for chronic indications poorly served by single-molecule agents, government support for standardising traditional Chinese medicine and Kampo within reimbursed healthcare, and quality upgrades in botanical raw material cultivation and fingerprint-based batch consistency analytics that reduce approval risk.
Asia Pacific is the largest and most institutionally embedded region, with reimbursed Kampo prescriptions in Japan and hospital-integrated traditional formulations in China and Taiwan, while North America and Europe grow through targeted prescription approvals in dermatology, gastroenterology and neurology. The competitive field is fragmented and regionally distinct, mixing Western specialty pharma with phytomedicine houses and Asian traditional medicine manufacturers.
The InsightAce study delivers US$ revenue forecasts across every source and formulation, therapeutic area, distribution channel and regional segment for 2026-2035, with trend analysis, competitive landscape review and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Botanical Drugs Market Snapshot
Chapter 4. Global Botanical Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Source & Formulation Estimates & Trend Analysis
5.1. Source & Formulation & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Source & Formulation:
5.2.1. Single-Herb Extract Drugs
5.2.2. Multi-Herb Formulation Drugs
5.2.3. Cannabis-Derived Prescription Drugs
5.2.4. Topical Botanical Preparations
5.2.5. Oral Botanical Preparations
Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Area:
6.2.1. Dermatology & Wound Care
6.2.2. Gastroenterology
6.2.3. Neurology
6.2.4. Respiratory Disorders
6.2.5. Cardiovascular Support
6.2.6. Other Therapeutic Areas
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. Distribution Channel & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Botanical Drugs Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Jazz Pharmaceuticals plc
10.2. Jaguar Health Inc. (Napo Pharmaceuticals)
10.3. Chiesi Farmaceutici S.p.A.
10.4. Dr. Willmar Schwabe Group
10.5. Bionorica SE
10.6. Tsumura & Co.
10.7. Kracie Holdings Ltd.
10.8. Tasly Pharmaceutical Group
10.9. Sun Ten Pharmaceutical Co. Ltd.
10.10. PuraPharm Corporation
10.11. Fougera Pharmaceuticals Inc.
10.12. Beijing Tongrentang Co. Ltd.
圖表清單 List of Tables & Figures
Table 1. Global Botanical Drugs Revenue Forecast by Source & Formulation, 2026-2035 (US$ Mn)
Figure 1. Regulatory Pathways for Botanical Drug Approval Across Major Markets
Table 2. Global Botanical Drugs Revenue Forecast by Therapeutic Area, 2026-2035 (US$ Mn)
Figure 2. Global Botanical Drugs Share by Therapeutic Area, 2026 & 2035
Table 3. Global Botanical Drugs Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 3. Approved Botanical Prescription Drugs and Active Botanical IND Landscape
Table 4. North America Botanical Drugs Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Kampo and Traditional Chinese Medicine Reimbursement Frameworks in Asia
Table 5. Europe Botanical Drugs Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Botanical Drugs Growth Opportunity Analysis
Table 6. Asia Pacific Botanical Drugs Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Standardisation and Batch Consistency Technologies for Multi-Constituent Drugs
Table 7. Strategic Developments Among Botanical Drug Developers
Figure 7. Competitive Positioning of Key Botanical Drug Companies
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們